Sign in to view content

Comparison of CRISPR-based Genome Editing of VEGF-A as Treatment Strategy for Choroidal Neovascularization

Glenn C. Yiu, MD, PhD

Video
Published 2019

Related

Avacincaptad Pegol, A Novel C5 Inhibitor, Demonstrates Continued Reduction in Geographic Atrophy Growth: 18-Month Results From GATHER1 Clinical Trial
Jason Hsu, MD
Annual Meeting Talks
2021
2-Year Outcomes From Randomized Trials of Anti-VEGF Treatments for Diabetic Retinopathy (DR) and Diabetic Macular Edema (DME)
Geeta A. Lalwani, MD
Annual Meeting Talks
2018
Geographic Trends in the Recruitment of Participants of Racial and Ethnic Minorities for Diabetic Retinopathy-Related Clinical Trials
Vivienne S. Hau, MD, PhD
Annual Meeting Talks
2023

Category: AMD-Neovascular

See more